OncoGenex gets addditional “fast track” designation for custirsen

According to a media release from OncoGenex, the U.S. Food & Drug Administration has granted a “fast track” designation to the evaluation of data from the so-called AFFINITY trial of custiren + carbazitaxel + prednisone as a second-line treatment for men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Palliative (and non-palliative) radiation therapy in late-stage prostate cancer today

The role of radiation therapy in the management of men with advanced (i.e., metastatic and castration-resistant) forms of prostate cancer has been evolving over the past 5 years or so. … READ MORE …

Reference pricing for PBRT in treatment of prostate cancer?

One of the lead specialists in the use of proton beam radiation therapy (PBRT) in the treatment of prostate cancer is suggesting that use of this technology should be reimbursed at the same rate as intensity-modulated radiation therapy (IMRT) — at least until we have better data. … READ MORE …

What’s being presented at the AUA in May: Part VI

There are five sessions on prostate cancer detection and screening at the annual meeting of the American Urological Association (AUA) this year that include 92 presentations and posters. For each session we have tried to identify at least one of the more interesting posters from the data to be presented. … READ MORE …

Current and future imaging techniques and recurrent prostate cancer

An article just reproduced on the Medscape Oncology web site provides a very readable review of what the authors describe as, “A paradigm shift from anatomic to functional and molecular imaging in the detection of recurrent prostate cancer”. … READ MORE …

How to mislead the public: a case study in apparent naivety

An article in today’s Daily Telegraph in the UK starts with the misleading statement that, “Up to half of men diagnosed with prostate cancer are being given ‘false hope’ by tests that are underestimating the severity of their disease, according to the authors of a new study.” … READ MORE …

Does cannabis have value in the management of prostate cancer?

If you do a PubMed search for “cannabis + prostate + cancer” you will find remarkably few articles that deal specifically with the impact of cannabis use and its relationship to prostate cancer — either in a positive or a negative sense. … READ MORE …

What’s being presented at the AUA in May: Part III

In the “Outstanding Posters” sessions at the annual meeting of the American Urological Association meeting upcoming in Orlando, there are several posters that deal specifically with prostate cancer-related issues. … READ MORE …

“Best care” doesn’t equate to better outcomes! That’s not good!

A poster by Schroeck et al. — to be presented on May 20 at the upcoming annual meeting of the American Urological Association (AUA) — presents the latest set of data suggesting that “best care” does not lead to appropriate outcomes quality for men receiving standard forms of treatment for localized prostate cancer. … READ MORE …

What’s being presented at the AUA in May: Part II

Here is information about more papers being presented at the annual meeting on the American Urological Association annual meeting in May. … READ MORE …

What’s being presented at the AUA in May: Part I

This is the first of several summary posts commenting briefly on new data to be presented at the annual meeting of the American Urological Association (AUA) this year. Individual presentations of important new data will be separately addressed … READ MORE …

Is AR-V7-positive status a contraindication to enzalutamide therapy?

According to a media release issued by the American Association for Cancer Research (AACR), it may be possible to identify some men with advanced prostate cancer who are highly likely to be resistant to treatment with enzalutamide. … READ MORE …

The potential of metformin in prostate cancer treatment: an update

We have previously commented (more than once) on the perception that metformin may have some value in the management of prostate cancer. A recently reported (albeit small), prospective Swiss study, has added to our knowledge in this regard. … READ MORE …

Medivation/Astellas seek expanded indication for enzalutamide in Europe

According to a media release this morning from Medivation and Astellas Pharma, the companies have completed submission of data in support of the expansion of the European Marketing Authorization for enzalutamide — to include men with chemotherapy-naive, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

New Phase I/II trial of InSightec’s MRI-guided focal ultrasound therapy

According to a media release issued yesterday by the City of Hope medical center in Los Angeles, they have become the first center in the USA to treat a patient with focused, MRI-guided, ultrasound technology using the InSightec system. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,074 other followers